$InspireMD (NSPR.US)$
Major Clinical Trial Alert: InspireMD's Revolutionary TCAR Stent Targets $1B+ Market

$InspireMD (NSPR.US)$ Reuters
4 mins ago
InspireMD and Namsa to Partner on Cguardians II Pivotal Clinical Trial of the Cguard Prime™ 80 Cm Carotid Stent System for Use in Tcar Procedures

$InspireMD (NSPR.US)$ InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the Cguard Prime Carotid Stent System

$InspireMD (NSPR.US)$
InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System
InspireMD (Nasdaq: NSPR) has received FDA approval for its Investigational Device Exemption (IDE) Application to initiate the CGUARDIANS II pivotal studyof the CGuard Prime 80cm Carotid Stent System for transcarotid revascularization (TCAR) procedures. This approval marks a significant milestone in the company's ...

$InspireMD (NSPR.US)$
InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System
PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS clinical study that were first presented at LINC 2024 in May
U.S. commercial launch anticipated in H1 2025, if approved
TEL AVIV, Israel and MIAMI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prev...

$InspireMD (NSPR.US)$ the mesh stint will become FDA approved. When is the question.

$InspireMD (NSPR.US)$ InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million

$InspireMD (NSPR.US)$ InspireMD Inc -U.S. Commercial Launch of Cguard™ Prime Carotid Stent System Anticipated in H1 2025, IF Approved

$InspireMD (NSPR.US)$ INSPIREMD INC -STUDY RESULTS TO SUPPORT A PREMARKET APPROVAL (PMA) APPLICATION TO FDA IN H2 2024
Reuters05/28/2024 08:53

$InspireMD (NSPR.US)$ InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.15) by 40 percent. This is a 60.38 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $1.511 billion which beat the analyst consensus estimate of $1.384 million by 109.08K percent. This is a 121.85K percent increase over sales of $1.239 million the same period...